Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Charles Iaconangelo

Showing results (1-10 of 6) with videos related to

Pageof 1
Sort By:
Applied Psychological Measurement|June 9, 2018
Model Similarity, Model Selection, and Attribute ClassificationWenchao Ma, Charles Iaconangelo, Jimmy de la Torre
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|November 28, 2021
Development of the Multiple Myeloma Symptom and Impact Questionnaire: A New Patient-Reported Outcome Instrument to Assess Symptom and Impacts in Patients With Multiple MyelomaKatharine S Gries, John Fastenau, Caroline Seo, et al.
Plos One|January 24, 2025
Psychometric validation of the Cystic Fibrosis Impact Questionnaire (CF-IQ): A patient-reported outcome assessing impacts of cystic fibrosisDaniel Serrano, Alyssa Uzumcu, Maya Gerstein, et al.
The Journal of Dermatological Treatment|July 15, 2025
The hf-PGA is a valid and reliable measure of hand/foot psoriasis severity in adults: results from a phase 2b clinical trialRobert Bissonnette, Ronald Vender, Andreas Pinter, et al.
Journal of the American Academy of Dermatology|November 16, 2024
FRONTIER-2: A phase 2b, long-term extension, dose-ranging study of oral JNJ-77242113 for the treatment of moderate-to-severe plaque psoriasisLaura K Ferris, Jerry Bagel, Yu-Huei Huang, et al.
Journal of the American Academy of Dermatology|May 17, 2026
Improvements in Clinical and Patient-Reported Outcomes and Durability of Response With the Targeted Oral Peptide Icotrokinra in Adolescents With Moderate-to-Severe Plaque Psoriasis: One-Year Results From the ICONIC-LEAD Randomized Controlled TrialJennifer Soung, Mark G Lebwohl, Adelaide Hebert, et al.
Pageof 1

Showing results (1-10 of 6) with videos related to

Sort By:
Pageof 1
Applied Psychological Measurement|June 9, 2018
Model Similarity, Model Selection, and Attribute ClassificationWenchao Ma, Charles Iaconangelo, Jimmy de la Torre
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|November 28, 2021
Development of the Multiple Myeloma Symptom and Impact Questionnaire: A New Patient-Reported Outcome Instrument to Assess Symptom and Impacts in Patients With Multiple MyelomaKatharine S Gries, John Fastenau, Caroline Seo, et al.
Plos One|January 24, 2025
Psychometric validation of the Cystic Fibrosis Impact Questionnaire (CF-IQ): A patient-reported outcome assessing impacts of cystic fibrosisDaniel Serrano, Alyssa Uzumcu, Maya Gerstein, et al.
The Journal of Dermatological Treatment|July 15, 2025
The hf-PGA is a valid and reliable measure of hand/foot psoriasis severity in adults: results from a phase 2b clinical trialRobert Bissonnette, Ronald Vender, Andreas Pinter, et al.
Journal of the American Academy of Dermatology|November 16, 2024
FRONTIER-2: A phase 2b, long-term extension, dose-ranging study of oral JNJ-77242113 for the treatment of moderate-to-severe plaque psoriasisLaura K Ferris, Jerry Bagel, Yu-Huei Huang, et al.
Journal of the American Academy of Dermatology|May 17, 2026
Improvements in Clinical and Patient-Reported Outcomes and Durability of Response With the Targeted Oral Peptide Icotrokinra in Adolescents With Moderate-to-Severe Plaque Psoriasis: One-Year Results From the ICONIC-LEAD Randomized Controlled TrialJennifer Soung, Mark G Lebwohl, Adelaide Hebert, et al.
Pageof 1